AzTrials
AzTrials

Nausea and Vomiting Chemotherapy-InducedBreast CancerNCT07470619

Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer

A study testing Twin Heart Meditation in people with Nausea and Vomiting Chemotherapy-Induced and Meditation Training, run by Near East University, Turkey at 1 site in Cyprus.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized clinical trial aimed to evaluate the effectiveness of Twin Hearts Meditation in reducing chemotherapy-induced nausea and vomiting among women with breast cancer undergoing chemotherapy. Read more about this study

Who is it for?
Ages 18 to 65 years, women onlyHealthy volunteers can take part
What is being tested?
Twin Heart Meditation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
102 participants
Where
1 siteCyprus
Study dates
15 Jun 2016to 30 Jun 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Women aged 18-65 years diagnosed with non-metastatic breast cancer.
  • Patients undergoing chemotherapy using standard chemotherapy regimens in the oncology unit.
  • Patients who had experienced nausea during at least one previous chemotherapy session.
  • Patients who voluntarily agreed to participate in the study and provided written informed consent

Who cannot join

  • Performing meditation fewer than three times per week during the intervention period.
  • Unwillingness to continue participation in the study.
  • Presence of medical conditions that may independently cause nausea, such as severe gastrointestinal disease, renal failure, or hepatic disease.

Trial locations and contacts

1 site in 1 country.

Cyprus1 site
  • Study site

    Nicosia, KKTC (Turkish Republic of Northern Cyprus), 99138

Other trials in Cyprus

About this study

Official title: The Effect of Meditation on Reducing Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer

This randomized clinical trial aimed to evaluate the effectiveness of Twin Hearts Meditation in reducing chemotherapy-induced nausea and vomiting among women with breast cancer undergoing chemotherapy. Chemotherapy-related nausea and vomiting are among the most distressing side effects of cancer treatment and can negatively affect patients' quality of life, nutritional status, and adherence to therapy.

The study focused on whether regular practice of this meditation technique could significantly reduce the severity of nausea and the frequency of vomiting episodes following chemotherapy. The main research questions were:

Read more

Does Twin Hearts Meditation reduce chemotherapy-induced nausea and vomiting among women with breast cancer? Can this complementary and non-invasive intervention be considered a supportive strategy for managing chemotherapy-related symptoms?

Participants were randomly assigned to either the intervention group, which practiced Twin Hearts Meditation, or the control group, which received routine care without meditation. The intervention group received a 30-minute guided meditation training session and practiced the meditation three times per week for two weeks.

Nausea severity and vomiting episodes were assessed using a nausea severity scale and a vomiting record flow sheet at baseline and at 6, 12, 18, and 24 hours after chemotherapy to evaluate the effectiveness of the intervention.

Read the detailed description

Study Title

The Effect of Twin Hearts Meditation on Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer

Study Purpose

The aim of this study was to investigate the effectiveness of Twin Hearts Meditation, a mind-body relaxation technique used in complementary and alternative medicine, in reducing chemotherapy-induced nausea and vomiting among women with breast cancer. Chemotherapy-related nausea and vomiting remain common and distressing side effects despite the routine use of antiemetic medications. This study evaluates whether meditation can serve as a supportive non-pharmacological intervention to reduce symptom severity and improve patient comfort during chemotherapy treatment.

Sample Size Determination

The study population consisted of women diagnosed with breast cancer who were receiving chemotherapy at the oncology unit of a public hospital in Iran. Based on findings from a similar study and using a mean comparison formula with a significance level of 0.05 and statistical power of 80%, the required sample size was calculated as 48 participants per group.

To account for possible dropout, 55 participants were recruited for each group. A total of 110 participants were initially enrolled and randomly allocated into experimental and control groups. During the study period, eight participants were excluded due to non-adherence to the meditation protocol or withdrawal from the study, resulting in a final sample of 102 participants.

Randomization was performed using a simple randomization method. Numbers from 1 to 110 were written on cards and placed in a container. The cards were then drawn sequentially and assigned alternately to the experimental and control groups to ensure equal allocation and reduce selection bias.

Blinding Procedure

This study was conducted as a single-blind randomized controlled trial. The researcher responsible for data collection was unaware of group allocation. In addition, the statistician who analyzed the data was blinded to group assignments and analyzed the coded data.

Tools of Data Collection

  1. Demographic Questionnaire This questionnaire collected baseline information including age, marital status, education level, occupation, place of residence, duration of illness, number of chemotherapy sessions, and chemotherapy regimen.
  2. Nausea Severity Scale (Visual Self-Reporting Scale) Nausea severity was assessed using a visual scale ranging from 0 to 10, where 0 indicated no nausea and 10 indicated the most severe nausea. Scores of 1-3 represented mild nausea, 4-6 moderate nausea, and 7-10 severe nausea.
  3. Vomiting Record Flow Sheet The frequency of vomiting episodes was recorded using a standardized flow sheet completed by participants after chemotherapy.

Nausea and vomiting were assessed at baseline and at 6, 12, 18, and 24 hours after chemotherapy.

Intervention

Experimental Group Participants received both theoretical and practical training in Twin Hearts Meditation delivered by the researcher, who was certified in teaching this meditation technique. The initial session included a supervised 30-minute guided meditation practice.

Participants were instructed to perform meditation three times per week for two weeks at home using an audio recording provided by the researcher.

  1. Five minutes of light physical exercises to promote relaxation and energy circulation. Praying
  2. Offering a short prayer or intention setting.
  3. Activation of the acupuncture point (heart chakra) by focusing on feelings of love and compassion.
  4. Activation of the acupuncture point (crown chakra) to enhance awareness and emotional balance.
  5. Focused meditation while concentrating on the word "Amen."
  6. Expressing gratitude for blessings received.
  7. Five minutes of physical activity to stabilize the body's energy after meditation

Control Group Participants in the control group received routine care and standard chemotherapy management without any meditation intervention.

Implementation Phase

After explaining the study objectives and procedures, written informed consent was obtained from all participants. Eligible patients were randomly assigned to either the experimental group or the control group. Meditation training sessions were conducted in a quiet room within the chemotherapy ward. Participants in both groups completed baseline and follow-up assessments during the chemotherapy cycle.

Ethical Considerations

This study was approved by the Ethics Committee of Arak University of Medical Sciences (Approval No. IR.ARAKMU.REC.1394.174). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (1964).

Participants were informed about the study procedures and their right to withdraw from the study at any time without consequences. Written informed consent was obtained from all participants, and confidentiality of participant data was maintained throughout the study.

Statistical Analysis

All data are analyzed using SPSS version 20. Descriptive statistics (mean, standard deviation, and frequencies) are used to summarize the data.

Inferential statistical methods include:

Kolmogorov-Smirnov test to assess normality Paired t-test to evaluate pre- and post-intervention changes within each group Independent t-test to compare differences between the two groups Chi-square test or Fisher's exact test for analysis of categorical variables A significance level of P < 0.05 is considered statistically significant for all analyses.

Being tested
Twin Heart Meditation
Keywords
Breast Neoplasms, Meditation, Nursing Care, Nausea
Medical subject headings
Nausea, Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Twin Heart MeditationBehavioural

    Participants in this group received Twin Hearts Meditation, a structured mind-body relaxation technique designed to promote emotional balance and psychological well-being. The intervention included a supervised 30-minute guided meditation session provided by a trained researcher in the chemotherapy unit.

    Participants were then instructed to continue the meditation practice at home for 30 minutes per session, at least three times per week for two weeks using an audio recording provided by the researcher.

    The meditation protocol included the following steps:

    • Light physical warm-up exercises to promote relaxation
    • Focused attention on positive emotions such as compassion and calmness
    • Guided meditation to promote mental relaxation and emotional balance
    • Silent concentration on a repeated phrase
    • Expression of gratitude
    • Closing relaxation exercises Regular telephone follow-up was conducted during the intervention period to support adherence to the meditation practice.
Study groups in NCT07470619
Study groupRoleWhat they receive
Twin Hearts MeditationExperimentalBehavioral: Twin Hearts Meditation Participants in this group receive Twin Hearts Meditation, a structured mind-body relaxation technique designed to promote emotional balance and psychological well-being. The intervention aims to reduce chemotherapy-induced nausea and vomiting by promoting relaxation, stress reduction, and improved emotional regulation in women with breast cancer undergoing chemotherapy
Receives: Behavioral: Twin Heart Meditation
Routine CareNo interventionParticipants in the control group received routine clinical care during chemotherapy and did not receive any additional behavioral intervention during the study period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Nausea Severity

    The primary outcome measure evaluates changes in the severity of chemotherapy-induced nausea among women with breast cancer undergoing chemotherapy. Nausea severity is assessed using a Visual Self-Reporting Nausea Scale, scored from 0 to 10, where 0 indicates no nausea and 10 indicates the most severe nausea. Higher scores indicate greater nausea severity

    Measured: Nausea severity is assessed at 6, 12, 18, and 24 hours after chemotherapy

Secondary outcomes (1)
  1. Frequency of Vomiting Episodes

    The secondary outcome measure evaluates the number of vomiting episodes experienced by participants after chemotherapy. Vomiting frequency is recorded using a vomiting episode recording chart completed by participants

    Measured: Vomiting frequency is assessed at 6, 12, 18, and 24 hours after chemotherapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study start15 Jun 2016
  3. Primary completion15 Jun 2016
  4. Study completion30 Jun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants were randomly allocated to one of two study arms: an experimental group receiving the Twin Hearts Meditation intervention and a control group receiving routine care. Both groups were observed and evaluated in parallel during the study period.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
102 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07470619
Sponsor's protocol ID
PVF2026CINV001
Acronym
Breast Cancer
Status last verified
Mar 2026
First submitted
9 Mar 2026
Last updated
13 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to make IPD available to other researchers

Questions about this trial

What is this clinical trial studying?

A study testing Twin Heart Meditation in people with Nausea and Vomiting Chemotherapy-Induced and Meditation Training, run by Near East University, Turkey at 1 site in Cyprus.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Cyprus. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Nausea Severity (time frame: Nausea severity is assessed at 6, 12, 18, and 24 hours after chemotherapy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in